TALLAHASSEE, Fla., Jan. 5, 2015 /PRNewswire/ -- Prevacus, Inc. today announced that Jake VanLandingham, Ph.D., President and Chairman of the Board of Prevacus, Inc., will make the inaugural corporate presentation on Wednesday, January 14, at 9:30am (pacific time) at the Biotech Showcase 2015 conference being held in San Francisco, CA.
Details of Prevacus’s presentation are as follows:
Event: | Biotech Showcase 2015 |
Date: | Wednesday, January 14, 2015 |
Time: | 9:30am (pacific time) |
Location: | Wyndham Parc 55 Hotel, Hearst Room |
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company’s first development candidate (PRV-002) represents a breakthrough strategy for treating concussion (mild traumatic brain injury or mTBI).
About Concussion
A concussion is a type of traumatic brain injury (TBI) caused by a traumatic force to the head or upper body causing the brain to shake inside the skull. The injury is defined as a concussion when it causes a change in mental status such as amnesia, disorientation, mental fogginess, confusion, nausea/vomiting, blurred vision or loss of consciousness. There are 21 symptoms demonstrated to be associated with concussion. Loss of consciousness does not indicate injury severity. Because no two concussions are exactly alike, and symptoms are not always definite, the injury’s severity, effects and recovery are sometimes difficult to determine.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid administered through the nasal cavity. PRV-002 carries with it equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain.
Forward-looking statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, future financial results, including operating expenses and cash position, pursuit of strategic options and pursuit of research and clinical development programs. Risks that contribute to the uncertain nature of the forward-looking statements include: we expect to incur losses for the foreseeable future and will need additional funds to finance our operations; our operating results fluctuate significantly; our estimates regarding our ability to initiate and/or complete our clinical trials and the timing and expense of these trials may not be accurate; enrollment in our clinical trials may be delayed; our clinical trials may not demonstrate the efficacy and safety of our product candidates; we may not be able to manufacture our product candidates on a commercial scale in a timely or cost-efficient manner; our estimates regarding expenses and capital requirements may not be accurate; regulatory developments in the United States and foreign countries may adversely affect our operations or prospects; we must obtain and maintain intellectual property protection for our product candidates; the loss of key scientific or management personnel could adversely affect our operations. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Jake VanLandingham, PhD
(850) 544-2962
jvan@prevacus.com
www.Prevacus.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/prevacus-to-present-at-biotech-showcase-2015-300015980.html
SOURCE Prevacus, Inc.
Help employers find you! Check out all the jobs and post your resume.
